

EMA/411560/2024

European Medicines Agency decision

P/0322/2024

of 13 September 2024

on the acceptance of a modification of an agreed paediatric investigation plan for iptacopan (Fabhalta), (EMA-002705-PIP03-20-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0322/2024

of 13 September 2024

on the acceptance of a modification of an agreed paediatric investigation plan for iptacopan (Fabhalta), (EMA-002705-PIP03-20-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0322/2021 issued on 12 August 2021,

Having regard to the application submitted by Novartis Europharm Limited on 26 April 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 July 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for iptacopan (Fabhalta), age-appropriate formulation, capsule, hard, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Europharm Limited, Vista Building Elm Park, Merrion Road, D04 A9N6 - Dublin 4, Ireland.

EMA/PDCO/240109/2024
Amsterdam, 26 July 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002705-PIP03-20-M01

Scope of the application

Active substance(s):

Iptacopan

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of paroxysmal nocturnal haemoglobinuria

Pharmaceutical form(s):

Age-appropriate formulation,

Capsule, hard

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted to the European Medicines Agency on 26 April 2024 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0322/2021 issued on 12 August 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 27 May 2024.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of paroxysmal nocturnal haemoglobinuria

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- age-appropriate formulation and capsule (hard), oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of paroxysmal nocturnal haemoglobinuria

2.1.1. Indication(s) targeted by the PIP

Treatment of paroxysmal nocturnal haemoglobinuria

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Age-appropriate formulation

Capsule, hard

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of an age-appropriate oral solid dosage form.
Non-clinical studies	Study 2 Definitive 52-week toxicity study in juvenile dogs with a 27-week recovery period.
Clinical studies	Study 3 - CLNP023I12201 Open-label, single-arm study to assess the safety, tolerability and pharmacokinetics of iptacopan in paediatric paroxysmal nocturnal haemoglobinuria (PNH) patients from 2 years to less than 18 years of age.

Extrapolation, modelling and simulation studies	Study 4 Population PK model to inform the optimal dose for Study 3 for children from 12 years to less than 18 years of age (Cohort 1). Study 5 Population PK model to inform the optimal dose for Study 3 for children from 2 years to less than 12 years of age (Cohort 2). Study 6 Paediatric population PK model to confirm the efficacy extrapolation strategy and confirm similarity in the exposure-response relationship in adults and children from 2 years to less than 18 years of age.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2032
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of paroxysmal nocturnal haemoglobinuria

Authorised indication(s):

- FABHALTA is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.
 - Invented name(s): FABHALTA
 - Authorised pharmaceutical form(s): Hard capsule (capsule)
 - Authorised route(s) of administration: oral use
 - Authorised via centralised procedure